Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience

Conclusion: Treatment with PD-1 inhibitors seems to have an efficacy signal and be well tolerated in PLWHIV, including impact on CD4+ lymphocyte count and HIV load, that should be monitored during treatment course (regarding real-life experience).
Source: AIDS - Category: Infectious Diseases Tags: FAST TRACK Source Type: research

Related Links:

Publication date: Available online 24 May 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Kasey Halsey, Jing Wu, Chang Su, Ben Hsieh, Thomas Yi, Scott A. Collins, Benjamin Kimia, Paul J. Zhang, Terrance Healey, Zishu Zhang, Harrison X. Bai
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Publication date: Available online 24 May 2020Source: European Journal of RadiologyAuthor(s): Lisa Loi, Ferdinand Zimmermann, Steffen Goerke, Andreas Korzowski, Jan-Eric Meissner, Katerina Deike-Hofmann, Anne Stieber, Peter Bachert, Mark Edward Ladd, Heinz-Peter Schlemmer, Sebastian Bickelhaupt, Sarah Schott, Daniel Paech
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionThe proposed multiparametric MRI-based SLICs+MTh method performs noninvasive assessment of NACT response in osteosarcoma that may improve cancer treatment monitoring, planning, and overall prognosis.Key Points• The simple linear iterative clustering supervoxels and Otsu multithresholding-based technique (SLICs+MTh) successfully estimates the proportion of necrosis, viable tumor, and edema in osteosarcoma in the course of chemotherapy.• The proposed technique is noninvasive and uses multiparametric MRI to measure necrosis as an indication of anticancer treatment response.• SLICs+MTh-based necrosis w...
Source: European Radiology - Category: Radiology Source Type: research
Publication date: Available online 24 May 2020Source: Pathology - Research and PracticeAuthor(s): Tania Franceschini, Elisa Capizzi, Francesco Massari, Riccardo Schiavina, Michelangelo Fiorentino, Francesca Giunchi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 5 May 2020Source: Joint Bone SpineAuthor(s): Laure Gossec, Anna Molto, Catherine Beauvais, Eric Senbel, René-Marc Flipo, Sophie Pouplin, Christophe Richez, Alain Saraux, Philippe Gaudin, Daniel Wendling, Maxime Dougados
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Publication date: Available online 29 April 2020Source: Joint Bone SpineAuthor(s): Delphine Villeneuve, Olivier Lidove, Pascal Chazerain, Jean-Marc Ziza, Thomas Sené
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Psychologists say anxiety and uncertainty prompt irrational decisions — like turning down a transplant when an organ becomes available.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Transplants Emergency Medical Treatment Coronavirus (2019-nCoV) Liver Fear (Emotion) Anxiety and Stress Cancer Heart your-feed-science your-feed-healthcare Source Type: news
U.S. drugmaker Regeneron Pharmaceuticals said on Monday it would repurchase about $5 billion of its shares directly from France's Sanofi, without altering their over-a-decade-long partnership.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
U.S. company Regeneron Pharmaceuticals said it had agreed to repurchase approximately $5 billion of its shares directly from French drugmaker Sanofi.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | France Health | Head and Neck Cancer | HIV AIDS | Immunotherapy | Infectious Diseases | Lung Cancer | Melanoma | Skin Cancer | Toxicology